Morgan Stanley Senti Biosciences, Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Oct 17, 2024	BUY	$0.24 - $0.4 $911 - $1,518	3,796 Added 237.25%	5,396 $1,000
Q2 2024 Aug 14, 2024	BUY	$0.24 - $0.4 $911 - $1,518	3,796 Added 237.25%	5,396 $1,000
Q1 2024 Oct 17, 2024	SELL	$0.36 - $0.66 $1,366 - $2,505	-3,796 Reduced 70.35%	1,600 $0
Q1 2024 Aug 16, 2024	SELL	$0.36 - $0.66 $1,366 - $2,505	-3,796 Reduced 70.35%	1,600 $0
Q1 2024 May 15, 2024	BUY	$0.36 - $0.66 $576 - $1,056	1,600 New	1,600 $0
Q3 2023 Nov 15, 2023	SELL	$0.41 - $0.99 $6,969 - $16,829	-16,999 Reduced 99.99%	1 $0
Q2 2023 Aug 14, 2023	SELL	$0.6 - $1.14 $139,714 - $265,458	-232,858 Reduced 93.2%	17,000 $10,000
Q1 2023 May 15, 2023	SELL	$1.15 - $2.06 $2,674 - $4,791	-2,326 Reduced 0.92%	249,858 $294,000
Q4 2022 Feb 14, 2023	SELL	$1.25 - $65.2 $122,787 - $6.4 Million	-98,230 Reduced 28.03%	252,184 $355,000
Q3 2022 Nov 14, 2022	SELL	$1.33 - $21.7 $797,260 - $13 Million	-599,444 Reduced 63.11%	350,414 $760,000
Q2 2022 Aug 15, 2022	BUY	$1.97 - $10.0 $1.87 Million - $9.5 Million	949,858 New	949,858 $1.87 Million

342K

Ticker SNTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,757,100
Market Cap $172M
Description
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antig...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.